Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?

Adv Rheumatol. 2019 Nov 14;59(1):49. doi: 10.1186/s42358-019-0096-2.

Abstract

Background: To investigate the link between carbamylated low-density lipoprotein (ca-LDL), atherogenic index of plasma (AIP), atherogenic coefficient (AC), Castelli's risk indices I and II (CRI I and II) and subclinic atherosclerosis in psoriatic arthritis (PsA).

Methods: Thirty-ninepatients and 19 age, sex, body mass index matched healthy controls were included. Insulin resistance (IR) was assessed with homeostasis of model assessment-IR (HOMA-IR). Carotid intima-media thickness (CIMT) was measured at both common carotid arteries and mean CIMT was calculated.

Results: The mean age was 49.50 ± 11.86 years and 64.1% were females in PsA group. In the PsA group, CIMT and HOMA-IR were significantly higher (p = 0.003, p = 0.043, respectively). AIP, AC, TG/HDL, CRI-1, CRI-2 and ca-LDL levels were similar between groups. In PsA group, CIMT was positively correlated with HOMA-IR, TG/HDL and AIP. Although ca-LDL was positively correlated with serum amyloid A (r = 0.744, p < 0.001), no correlation was detected between ca-LDL and CIMT (r = 0.215, p = 0.195). PsA patients with IR tended to have higher ca-LDL levels than patients without IR, but this difference lacked statistical significance (33.65 ± 26.94, 28.63 ± 28.06, respectively, p = 0.237).

Conclusions: A significant increase in CIMT was seen in PsA patients without clinically evident cardiovascular disease or any traditional atherosclerosis risk factors. CIMT was correlated with HOMA-IR, TG/HDL and AIP.

Keywords: Atherogenic indexes; Atherosclerosis; Ca-LDL; Carotid intima-media thickness; Psoriatic arthritis.

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Psoriatic / blood*
  • Arthritis, Psoriatic / complications
  • Arthritis, Psoriatic / drug therapy
  • Atherosclerosis / blood*
  • Atherosclerosis / etiology
  • Biomarkers / blood
  • Carotid Intima-Media Thickness*
  • Case-Control Studies
  • Female
  • Homeostasis
  • Humans
  • Insulin Resistance
  • Leflunomide / therapeutic use
  • Lipoproteins, HDL / blood
  • Lipoproteins, LDL / blood*
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Risk
  • Statistics, Nonparametric
  • Triglycerides / blood
  • Tumor Necrosis Factor Inhibitors / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antirheumatic Agents
  • Biomarkers
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Triglycerides
  • Tumor Necrosis Factor Inhibitors
  • carbamyl-LDL
  • Leflunomide
  • Methotrexate